1.黑龙江中医药大学,教育部北药基础与应用研究重点实验室(黑龙江 哈尔滨 150040)
张玉昆,男,博士,黑龙江中医药大学中药学博士后流动站在站人员,高级实验师,主要从事方剂药理与药学研究工作
肖洪彬,教授,博士研究生导师;E-mail:hrbxiaohongbin@126.com
牛雯颖,研究员,硕士研究生导师;E-mail:121505982@qq.com。
扫 描 看 全 文
张玉昆, 冯月男, 卞敬琦, 等. 丹参饮对高脂血症模型大鼠降脂机制的研究[J]. 上海中医药杂志, 2021,55(11):80-84.
Yukun ZHANG, Yuenan FENG, Jingqi BIAN, et al. Study of Danshen Yin on lipid-lowering mechanism in hyperlipemia model rats[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(11):80-84.
张玉昆, 冯月男, 卞敬琦, 等. 丹参饮对高脂血症模型大鼠降脂机制的研究[J]. 上海中医药杂志, 2021,55(11):80-84. DOI: 10.16305/j.1007-1334.2021.2104070.
Yukun ZHANG, Yuenan FENG, Jingqi BIAN, et al. Study of Danshen Yin on lipid-lowering mechanism in hyperlipemia model rats[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(11):80-84. DOI: 10.16305/j.1007-1334.2021.2104070.
目的,2,探讨丹参饮对高脂饲料长期喂养复制高脂血症模型大鼠脂质代谢的作用效果及机制。,方法,2,70只Wistar大鼠,随机分为基础组14只和高脂组56只。基础组喂食基础饲料,高脂组喂食高脂饲料,于第8周检测大鼠血脂水平。基础组中符合要求的大鼠作为空白组,高脂组中符合要求的大鼠根据体质量和血脂水平,随机分为辛伐他汀对照组(辛伐组,0.004 g/kg)、丹参饮高剂量组(丹高组,生药含量3.6 g/kg)、丹参饮低剂量组(丹低组,生药含量0.9 g/kg)和模型组。给药4周后取材,检测大鼠血脂生化指标(TC、TG、HDL-C、LDL-C)、血浆中脂质代谢活性酶(HL、LCAT、PLTP)水平,HE染色观察肝组织病理形态。,结果,2,与模型组比较,丹高组血浆中TC、TG、LDL-C水平降低(,P,<,0.05),HDL-C水平升高(,P,<,0.05);丹低组血浆中TC、TG水平降低(,P,<,0.05);丹高组、丹低组血浆中HL水平升高(,P,<,0.05,,P,<,0.01);丹高组、丹低组肝组织中LPL、MTP水平升高(,P,<,0.05),HMG-coA还原酶水平降低(,P,<,0.05)。丹高组、丹低组均能显著改善高脂血症模型大鼠肝脏组织病理形态,且丹高组效果较丹低组病理改善更加明显。,结论,2,丹参饮具有降脂作用,其机制可能与其影响脂质的吸收、合成、转运及代谢过程有关。
Objective,2,To explore the effect and mechanism of Danshen Yin on lipid metabolism in rats with hyperlipidemia induced by long-term feeding with high-fat diet.,Methods,2,Totally 70 Wistar rats were randomly divided into basic group (,n,=14 ) and high-fat group (,n,=56 ). The rats in the basic group were fed with basic diet, and the rats in the high-fat group were fed with high-fat diet. The blood lipid level of the animals was measured in the eighth week. The rats in the basic group met the requirements were taken as the blank group. According to body weight and blood lipid levels, the successful modeling rats in the high-fat group were randomly divided into model group, simvastatin control group (0.004 g/kg ), high-dose Danshen Yin group (3.6 g/kg crude drug ) and low-dose Danshen Yin group (0.9 g/kg crude drug). Four weeks after administration, the blood lipid biochemical indexes (TC, TG, HDL-C, LDL-C) and the levels of lipid metabolic enzymes (HL, LCAT, PLTP) in plasma were detected and the pathological morphology of liver tissue was observed by HE staining.,Results,2,Compared with the model group, the plasma contents of TC, TG and LDL-C in high-dose Danshen Yin group were decreased (,P,<,0.05), while the content of HDL-C was increased (,P,<,0.05), and the plasma contents of TC and TG in low-dose Danshen Yin group were decreased (,P,<,0.05). HL content in plasma of rats in high-dose and low-dose Danshen Yin groups was increased (,P,<,0.05,P,<,0.01). The contents of LPL and MTP in liver tissues of rats in the high-dose and low-dose Danshen Yin groups were increased (,P,<,0.05), and the content of HMG-coA reductase was decreased (,P,<,0.05). Both Danshen Yin groups could significantly improve the pathological morphology of liver tissue in hyperlipidemia model rats, and the effect of high-dose Danshen Yin group was more obvious than that of low-dose Danshen Yin group.,Conclusion,2,Danshen Yin has significant lipid-lowering effect, and its mechanism may be related to the effect of Danshen Yin on lipid absorption, synthesis, transportation and metabolism.
高脂血症丹参饮活血化瘀脂质代谢模型大鼠中药研究
hyperlipemiaDanshen Yinactivating blood and resolving stasislipid metabolismmodel ratstraditional Chinese herbal medicine research
ZHANG H L, ZOU X Q, HUANG Q Y, et al. Effects of Kudingcha nanoparticles in hyperlipidaemic rats induced by a high fat diet[J]. Cell Physiol Biochem, 2018, 45(6): 2257-2267.
何慧,周江,邓德强. 平胃三黄汤治疗糖尿病合并脂代谢紊乱临床观察[J]. 中医药学报,2016, 44(4): 122-124.
石燕萍,韩俊阁,曾双辉,等. 自拟养阴降浊汤联合耳穴贴压疗法治疗糖尿病合并高脂血症的临床研究[J]. 中医药学报,2016, 44(6): 119-121.
何娟,沈浓儿,黄炜,等. 不同剂量的辛伐他汀治疗高脂血症的临床观察[J]. 中国药房,2015, 26(9): 1194-1196.
孔令雷,杜冠华. 丹参饮的现代研究进展[J]. 中药药理与临床,2019, 35(3): 197-200.
陈惠,孙朦朦,安然,等. 丹参饮在心血管疾病中的应用研究[J]. 吉林中医药,2013, 33(1): 27-30.
康天济,康广盛. 丹参饮的临证应用[J]. 中医药信息,2005, 22(5): 66.
潘小平,黄政德,杨伟峰,等. 加味丹参饮治疗原发性高脂血症合并动脉硬化40例总结[J]. 湖南中医杂志,2013, 29(7): 12-14.
胡振波,姜贺,徐京育. 复方丹参饮治疗慢性稳定型心绞痛伴高脂血症的临床观察[J]. 中医药学报,2009, 37(1): 31-32.
牛雯颖,王莉丽,冯月男,等. 补阳还五汤、少腹逐瘀汤和丹参饮对高脂血症模型大鼠红细胞膜组分影响的研究[J].上海中医药杂志,2018, 52(8): 78-82.
李环,焦亚斌. 丹参饮精品中药与普通中药对动脉粥样硬化模型大鼠药理作用的比较[J]. 长春中医药大学学报,2014, 30(6): 978-980.
CHEN J, DENG J, ZHANG Y Y, et al. Lipid-lowering effects of Danhong injection on hyperlipidemia rats[J]. J Ethnopharmacol, 2014, 154(2): 437-442.
LIM C, LIM S, LEE B, et al. Effect of methanol extract of Salviae miltiorrhizae Radix in high-fat diet-induced hyperlipidemic mice[J]. Chin Med, 2017(12): 29.
JIA L, SONG N, YANG G L, et al. Effects of Tanshinone IIA on the modulation of miR-33a and the SREBP-2/Pcsk9 signaling pathway in hyperlipidemic rats[J]. Mol Med Rep, 2016, 13(6): 4627-4635.
孙晓鹏,郭康,郭志坤. 高脂血症大鼠心肌中脂滴分布和H-FABP表达变化[J]. 中国临床解剖学杂志,2021, 39(1): 49-54.
杜海霞,周惠芬,何昱,等. 基于脂质代谢紊乱探讨丹红注射液对高脂血症大鼠的降脂作用及机制[J]. 中国中药杂志,2020, 45(13): 3203-3210.
诸骏仁,高润霖,赵水平,等. 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志,2016, 31(10): 937-953.
陈良金,周继刚,张继红,等. 豁痰化瘀降脂煎剂治疗高脂血症42例疗效观察[J]. 中国药房,2010, 21(39): 3735-3736.
陈亚红,刘传鑫,何涛,等. 丹参饮治疗糖尿病心肌病的网络药理学研究[J]. 中草药,2019, 50(5): 1164-1174.
ILLINGWORTH D R. Lipoprotein metabolism[J]. Am J Kidney Dis, 1993, 22(1): 90-97.
MUSSO G, GAMBINO R, CASSADER M. Lipoprotein metabolism mediates the association of MTP polymorphism with beta-cell dysfunction in healthy subjects and in nondiabetic normolipidemic patients with nonalcoholic steatohepatitis[J]. J Nntr Biochem, 2010, 21(9): 834-840.
PEREIRA I V, STEFANO J T, OLIVEIRA C P. Microsomal triglyceride transfer protein and nonalcoholic fatty liver disease[J]. Expert Rev Gastroenterol Hepatol, 2011, 5(2): 245-251.
CARULLI L, CANEDI I, RONDINELLA S, et al. Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymer phismis associated with non-alcoholic steatohepatitis [J]. Dig Liver Dis, 2009, 41(11): 823-828.
IQBAL J, MASCARENO E, CHUA S, et al. Leptin-mediated differential regulation of microsomal triglyceride transfer protein in the intestine and liver affects plasma lipids[J]. J Biol Chem, 2020, 295(13): 4101-4113.
KHAN M T, DALVIN S, NILSEN F et al. Microsomal triglyceride transfer protein in the ectoparasitic crustacean salmon louse (Lepeophtheirus salmonis) [J]. J Lipid Res, 2017, 58(8): 1613-1623.
HUUSKONEN J, OLKKONEN V M, EHNHOLM C, et al. Phospholipid transfer is a prerequisite for PLTP-mediated HDL conversion[J]. Biochemistry, 2000, 39(51): 16092-16098.
FRIESEN J A, RODWELL V W. The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases[J]. Genome Biol, 2004,5(11): 248.
OLIVECRONA G. Role of lipoprotein lipase in lipid metabolism[J]. Curr Opin Lipidol, 2016, 27(3): 233-241.
PERRET B, MABILE L, MARTINEZ L, et al. Hepatic lipase: structure/function relationship, synthesis, and regulation[J]. J Lipid Res, 2002, 43(8): 1163-1169.
KOBAYASHI J. Which is the best predictor for the development of atherosclerosis among circulating lipoprotein lipase, hepatic lipase,and endothelial lipase?[J]. J Atheroscler Thromb, 2019, 26(9): 758-759.
谢玲,胡小军,訾璐,等. 三七降脂粉对高脂血症合并脂肪肝患者降血脂作用的影响研究[J]. 世界中医药,2016, 11(10): 2002-2004.
0
浏览量
887
下载量
0
CSCD
3
CNKI被引量
关联资源
相关文章
相关作者
相关机构